A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

Launched by ELI LILLY AND COMPANY · Feb 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called retatrutide, which is being tested to see how well it helps people with obesity maintain their weight loss. The study will last around 125 weeks and is divided into two parts. First, all participants will take a specific dose of retatrutide for 80 weeks. Then, in the next 36 weeks, participants will be randomly assigned to continue with their retatrutide dose, switch to a higher dose, or receive a placebo (a treatment that looks like the medication but has no active ingredients).

To join the study, participants need to be adults aged 18 and older who have obesity and have tried to lose weight through diet without success. However, some individuals won't be able to participate if they have recently lost or gained a significant amount of weight, have certain medical conditions (like diabetes or heart issues), or have undergone prior obesity treatments. Throughout the trial, participants will receive regular health check-ups and support while taking the medication. This study aims to gather important information about how retatrutide can help people keep their weight off in the long term.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight
• Exclusion Criteria:
• • Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening
• • Have a prior or planned surgical treatment for obesity
• • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity
• • Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes
• • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
• * Have had within the past 90 days before screening:
• • acute myocardial infarction
• • cerebrovascular accident (stroke)
• • hospitalization for unstable angina, or
• • hospitalization due to congestive heart failure
• • Have New York Heart Association Functional Classification Class IV congestive heart failure
• • Have a history of chronic or acute pancreatitis
• • Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening